Walleye Capital LLC Purchases 52,890 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Walleye Capital LLC increased its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 176.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 82,890 shares of the company's stock after acquiring an additional 52,890 shares during the quarter. Walleye Capital LLC owned approximately 0.28% of Dianthus Therapeutics worth $1,807,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Invesco Ltd. lifted its stake in shares of Dianthus Therapeutics by 7.4% in the 4th quarter. Invesco Ltd. now owns 11,521 shares of the company's stock valued at $251,000 after purchasing an additional 790 shares during the period. SG Americas Securities LLC lifted its stake in shares of Dianthus Therapeutics by 9.2% in the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company's stock valued at $210,000 after purchasing an additional 814 shares during the period. Barclays PLC lifted its stake in shares of Dianthus Therapeutics by 2.6% in the 4th quarter. Barclays PLC now owns 42,766 shares of the company's stock valued at $933,000 after purchasing an additional 1,082 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Dianthus Therapeutics by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company's stock valued at $3,641,000 after buying an additional 1,092 shares during the last quarter. Finally, R Squared Ltd purchased a new position in Dianthus Therapeutics during the fourth quarter valued at $26,000. 47.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on DNTH shares. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Guggenheim reiterated a "buy" rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Wedbush reissued an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $54.33.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH traded up $0.22 during midday trading on Thursday, hitting $21.78. 31,811 shares of the company's stock traded hands, compared to its average volume of 260,499. The firm has a fifty day moving average of $20.09 and a 200 day moving average of $22.99. Dianthus Therapeutics, Inc. has a 1 year low of $13.37 and a 1 year high of $32.27. The stock has a market capitalization of $699.77 million, a price-to-earnings ratio of -8.67 and a beta of 1.62.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $1.33 million for the quarter, compared to analysts' expectations of $1.40 million. On average, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.